These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

824 related articles for article (PubMed ID: 37520530)

  • 21. A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2.
    Wang S; Wang CY; Kuo HK; Peng WJ; Huang JH; Kuo BS; Lin F; Liu YJ; Liu Z; Wu HT; Ding S; Hou KL; Cheng J; Yang YT; Jiang MH; Wang MS; Chen T; Xia WG; Lin E; Hung CH; Chen HJ; Shih Z; Lin YL; Ryan V; Hu MM; Heppner DG; Malherbe DC; Periasamy S; Kuzmina N; Subramani C; Hellerstein M; Monath TP; Rumyantsev A; Bukreyev A; Guirakhoo F
    Emerg Microbes Infect; 2022 Dec; 11(1):2724-2734. PubMed ID: 36287714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intranasal administration of a live-attenuated recombinant newcastle disease virus expressing the SARS-CoV-2 Spike protein induces high neutralizing antibody levels and protects from experimental challenge infection in hamsters.
    de Swart RL; de Leeuw OS; Oreshkova N; Gerhards NM; Albulescu IC; Vreman S; Gonzales JL; Maas R; van Kuppeveld FJM; Soema P; Bosch BJ; Peeters BPH
    Vaccine; 2022 Aug; 40(33):4676-4681. PubMed ID: 35820941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera.
    Espeseth AS; Yuan M; Citron M; Reiserova L; Morrow G; Wilson A; Horton M; Rukhman M; Kinek K; Hou F; Li SL; Li F; Choi Y; Heidecker G; Luo B; Wu G; Zhang L; Strable E; DeStefano J; Secore S; Mukhopadhyay TK; Richardson DD; Sayeed E; Welch LS; Bett AJ; Feinberg MB; Gupta SB; Cooper CL; Parks CL
    EBioMedicine; 2022 Aug; 82():104203. PubMed ID: 35915046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta.
    Carter B; Huang P; Liu G; Liang Y; Lin PJC; Peng BH; McKay LGA; Dimitrakakis A; Hsu J; Tat V; Saenkham-Huntsinger P; Chen J; Kaseke C; Gaiha GD; Xu Q; Griffiths A; Tam YK; Tseng CK; Gifford DK
    Front Immunol; 2023; 14():1135815. PubMed ID: 36969239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
    Hemmi T; Ainai A; Hashiguchi T; Tobiume M; Kanno T; Iwata-Yoshikawa N; Iida S; Sato Y; Miyamoto S; Ueno A; Sano K; Saito S; Shiwa-Sudo N; Nagata N; Tamura K; Suzuki R; Hasegawa H; Suzuki T
    Vaccine; 2022 Sep; 40(41):5892-5903. PubMed ID: 36064667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
    Americo JL; Cotter CA; Earl PL; Liu R; Moss B
    Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2202069119. PubMed ID: 35679343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoinformatics Identification of the Conserved and Cross-Reactive T-Cell Epitopes of SARS-CoV-2 with Human Common Cold Coronaviruses, SARS-CoV, MERS-CoV and Live Attenuated Vaccines Presented by HLA Alleles of Indonesian Population.
    Gustiananda M; Julietta V; Hermawan A; Febriana GG; Hermantara R; Kristiani L; Sidhartha E; Sutejo R; Agustriawan D; Andarini S; Parikesit AA
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cross-Protection Induced by Highly Conserved Human B, CD4
    Prakash S; Dhanushkodi NR; Zayou L; Ibraim IC; Quadiri A; Coulon PG; Tifrea DF; Suzler B; Amin M; Chilukuri A; Edwards RA; Vahed H; Nesburn AB; Kuppermann BD; Ulmer JB; Gil D; Jones TM; BenMohamed L
    bioRxiv; 2023 May; ():. PubMed ID: 37292861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Towards the development of an epitope-focused vaccine for SARS-CoV-2.
    Cervantes-Torres J; Rosales-Mendoza S; Cabello C; Montero L; Hernandez-Aceves J; Granados G; Calderón-Gallegos A; Zúñiga-Flores F; Ruiz-Rivera M; Abarca-Magaña JC; Ortega-Francisco S; Olguin-Alor R; Díaz G; Paczka-Garcia F; Zavala-Gaytan R; Vázquez-Ramírez R; Ayón-Nuñez DA; Carrero JC; Rios D; Jasso-Ramírez M; Vázquez-Hernández R; Venegas D; Garzón D; Cobos L; Segura-Velázquez R; Villalobos N; Meneses G; Zúñiga J; Gamba G; Cárdenas G; Hernández M; Parkhouse ME; Romano MC; Alonso Herrera L; Bobes RJ; Pérez-Tapia M; Huerta L; Fierro N; Gracia I; Soldevilla G; Fragoso G; Suárez-Güemes F; Laclette JP; Sciutto E
    Vaccine; 2022 Oct; 40(45):6489-6498. PubMed ID: 36195474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals.
    Ye ZW; Ong CP; Tang K; Fan Y; Luo C; Zhou R; Luo P; Cheng Y; Gray VS; Wang P; Chu H; Chan JF; To KK; Chen H; Chen Z; Yuen KY; Ling GS; Yuan S; Jin DY
    Cell Mol Immunol; 2022 May; 19(5):588-601. PubMed ID: 35352010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bacteria-enabled oral delivery of a replicon-based mRNA vaccine candidate protects against ancestral and delta variant SARS-CoV-2.
    Jawalagatti V; Kirthika P; Hewawaduge C; Yang MS; Park JY; Oh B; Lee JH
    Mol Ther; 2022 May; 30(5):1926-1940. PubMed ID: 35123065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models.
    Ma J; Yakass MB; Jansen S; Malengier-Devlies B; Van Looveren D; Sanchez-Felipe L; Vercruysse T; Weynand B; Javarappa MPA; Quaye O; Matthys P; Roskams T; Neyts J; Thibaut HJ; Dallmeier K
    EBioMedicine; 2022 Sep; 83():104240. PubMed ID: 36041265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Intranasal vaccine against COVID-19 based on a recombinant variant of the Sendai virus (Paramyxoviridae:
    Kudrov GA; Zainutdinov SS; Grazhdantseva AA; Shipovalov AV; Sivolobova GF; Semenova AV; Merkuleva IA; Shcherbakov DN; Taranov OS; Zaykovskaya AV; Shulgina IS; Pyankov OV; Kochneva GV
    Vopr Virusol; 2023 Jul; 68(3):215-227. PubMed ID: 37436413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ad5-nCoV Vaccination Could Induce HLA-E Restricted CD8
    Wang Y; Yang L; Tang K; Zhang Y; Zhang C; Zhang Y; Jin B; Zhang Y; Zhuang R; Ma Y
    Viruses; 2023 Dec; 16(1):. PubMed ID: 38257752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants.
    Kingstad-Bakke B; Lee W; Chandrasekar SS; Gasper DJ; Salas-Quinchucua C; Cleven T; Sullivan JA; Talaat A; Osorio JE; Suresh M
    Proc Natl Acad Sci U S A; 2022 May; 119(20):e2118312119. PubMed ID: 35561224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine.
    Hawman DW; Meade-White K; Clancy C; Archer J; Hinkley T; Leventhal SS; Rao D; Stamper A; Lewis M; Rosenke R; Krieger K; Randall S; Khandhar AP; Hao L; Hsiang TY; Greninger AL; Gale M; Berglund P; Fuller DH; Rosenke K; Feldmann H; Erasmus JH
    EBioMedicine; 2022 Sep; 83():104196. PubMed ID: 35932641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.
    Du Y; Xu Y; Feng J; Hu L; Zhang Y; Zhang B; Guo W; Mai R; Chen L; Fang J; Zhang H; Peng T
    Vaccine; 2021 Apr; 39(16):2280-2287. PubMed ID: 33731271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants.
    Jiang L; Driedonks TAP; Jong WSP; Dhakal S; Bart van den Berg van Saparoea H; Sitaras I; Zhou R; Caputo C; Littlefield K; Lowman M; Chen M; Lima G; Gololobova O; Smith B; Mahairaki V; Riley Richardson M; Mulka KR; Lane AP; Klein SL; Pekosz A; Brayton C; Mankowski JL; Luirink J; Villano JS; Witwer KW
    J Extracell Vesicles; 2022 Mar; 11(3):e12192. PubMed ID: 35289114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 Vaccine.
    Lam JH; Shivhare D; Chia TW; Chew SL; Sinsinbar G; Aw TY; Wong S; Venkataraman S; Lim FWI; Vandepapeliere P; Nallani M
    ACS Nano; 2022 Oct; 16(10):16757-16775. PubMed ID: 36223228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.